FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.
You may also be interested in...
Earnings Calls In Brief
Hologic 3D mammography
Earnings Calls In Brief
Hologic 3D mammography
Medtronic Achieves CoreValve Trial Revisions To Keep Pace With Edwards
Enrollment in one section of Medtronic's U.S. pivotal study for its CoreValve transcatheter aortic heart valve will be easier now that FDA has granted conditional approval to modify the trial.